TY - JOUR
T1 - Controlled trial of furosemide therapy in infants with chronic lung disease
AU - McCann, Ellen M.
AU - Lewis, Kathleen
AU - Deming, Douglas D.
AU - Donovan, Margaret J.
AU - Brady, June P.
N1 - Funding Information:
From the Cardiovascular Research Institute, University of California, San Francisco, and the Department of Pediatrics, Children's Hospital of San Francisco. Supported by Grant HL24075 from the National Heart, Lung, and Blood Institute. Presented at the Society for Pediatric Research Meeting, Washington, D,C.. May 1983. Submitted in partial fulfillment of a masters in science degree at San Francisco State University, 1983. Submitted for publication June 18, 1984; accepted Nov. 27, 1984. Reprint requests: Ellen M. McCann, M.S., Children's Hospital of San Francisco, Department of Neonatal Services, 3700 California St.i San Francisco, CA 94118.
PY - 1985/6
Y1 - 1985/6
N2 - To study the effects of furosemide therapy in infants with chronic lung disease (CLD), a double-blind controlled trial was designed. Seventeen infants with evidence of CLD (oxygen requirements >30% at >3 weeks of age and chest radiographic findings consistent with CLD) were studied. Pulmonary function was measured immediately before, and after 48 hours and 7 days of treatment with furosemide (1 mg/kg/12 hr intravenously or 2 mg/kg/12 hr orally) or placebo. Clinical status improved in six of seven infants who received furosemide and in two of 10 infants who received placebo (P<0.002). In the furosemide group, ventilator and oxygen requirements decreased (P<0.003); minute ventilation, alveolar ventilation, and dynamic compliance increased; and venous admixture decreased (P<0.05). There were no significant changes in the placebo group. Our findings suggest that furosemide significantly improves lung function during therapy in infants with CLD and allows earlier weaning from ventilatory support and supplemental oxygen.
AB - To study the effects of furosemide therapy in infants with chronic lung disease (CLD), a double-blind controlled trial was designed. Seventeen infants with evidence of CLD (oxygen requirements >30% at >3 weeks of age and chest radiographic findings consistent with CLD) were studied. Pulmonary function was measured immediately before, and after 48 hours and 7 days of treatment with furosemide (1 mg/kg/12 hr intravenously or 2 mg/kg/12 hr orally) or placebo. Clinical status improved in six of seven infants who received furosemide and in two of 10 infants who received placebo (P<0.002). In the furosemide group, ventilator and oxygen requirements decreased (P<0.003); minute ventilation, alveolar ventilation, and dynamic compliance increased; and venous admixture decreased (P<0.05). There were no significant changes in the placebo group. Our findings suggest that furosemide significantly improves lung function during therapy in infants with CLD and allows earlier weaning from ventilatory support and supplemental oxygen.
UR - https://www.scopus.com/pages/publications/0021819962
UR - https://www.scopus.com/pages/publications/0021819962#tab=citedBy
U2 - 10.1016/S0022-3476(85)80252-3
DO - 10.1016/S0022-3476(85)80252-3
M3 - Article
C2 - 3889258
SN - 0022-3476
VL - 106
SP - 957
EP - 962
JO - Journal of Pediatrics
JF - Journal of Pediatrics
IS - 6
ER -